


IN THE CLAIMS:

Please cancel claims 1-24, 31-46, and 51-66.

Please enter the following amended claims:

25. (Amended) A compound of the formula II:



wherein stereocenters * are R or S;

dotted lines indicate that a double bond may be present or absent, and the double bond geometry may be E or Z;

A, A', and C are independently H, C₁-C₂₀ acylamino, C₁-C₂₀ acyloxy, C₁-C₂₀ alkoxy carbonyl, C₁-C₂₀ alkoxy, C₁-C₂₀ linear or branched alkylamino, C₁-C₂₀ alkylcarboxylamino, C₁-C₂₀ carbalkoxy; carboxyl, cyano, halo, hydroxy; and t, u, and w are independently integers from 0 to 3;

B and B' are independently H, C₁-C₂₀ acylamino, C₁-C₂₀ acyloxy, C₁-C₂₀ alkanoyl, C₁-C₂₀ alkenoyl, C₁-C₂₀ alkenyl, C₁-C₂₀ alkoxy carbonyl, C₁-C₂₀ linear or branched alkoxy, C₁-C₂₀ linear or branched alkylamino, C₁-C₂₀ alkylcarboxylamino, C₁-C₂₀ carbalkoxy; C₆-C₂₀ aroyl, C₆-C₂₀ aralkanoyl, carboxyl, cyano, halo, hydroxy; and x and y are independently integers from 0 to 3;

R', R'', and R''' are independently H or C₁-C₂₀ linear or branched alkyl or alkenyl groups which may contain substituents, COOH, C₁-C₂₀ alkoxy carbonyl, NH₂, CONH₂, C₁-C₂₀ acylamino, OH, C₁-C₂₀ alkoxy, halo or cyano. (X=NH, O) S, S=O, or SO₂.


26. (Amended) A pharmaceutical composition containing a blood glucose lowering effective amount of a compound of the formula II in a pharmaceutically acceptable carrier.

wherein stereocenters * are R or S;

dotted lines indicate that a double bond may be present or absent, and the double bond geometry may be E or Z;

A, A', and C are independently H, C₁-C₂₀ acylamino, C₁-C₂₀ acyloxy, C₁-C₂₀ alkoxy carbonyl, C₁-C₂₀ alkoxy, C₁-C₂₀ linear or branched alkylamino, C₁-C₂₀ alkylcarboxylamino, C₁-C₂₀ carbalkoxy; carboxyl, cyano, halo, hydroxy; and t, u, and w are independently integers from 0 to 3;

B and B' are independently H, C₁-C₂₀ acylamino, C₁-C₂₀ acyloxy, C₁-C₂₀ alkanoyl, C₁-C₂₀ alkenoyl, C₁-C₂₀ alkenyl, C₁-C₂₀ alkoxy carbonyl, C₁-C₂₀ linear or branched alkoxy,




(SOB)
(A7)
CONT

C₁–C₂₀ linear or branched alkylamino, C₁–C₂₀ alkylcarboxylamino, C₁–C₂₀ carbalkoxy; C₆–C₂₀ aroyl, C₆–C₂₀ aralkanoyl, carboxyl, cyano, halo, hydroxy; and x and y are independently integers from 0 to 3;

R', R'', and R''' are independently H or C₁–C₂₀ linear or branched alkyl or alkenyl groups which may contain substituents, COOH, C₁–C₂₀ alkoxy carbonyl, NH₂ CONH₂, C₁–C₂₀ acylamino, OH, C₁–C₂₀ alkoxy, halo or cyano. X=NH, O, S, S=O, or SO₂.

27. (Amended) A method for lowering blood glucose in a subject comprising administering to said subject an effective blood glucose lowering amount of a composition of the formula II.



wherein stereocenters * are R or S;

dotted lines indicate that a double bond may be present or absent, and the double bond geometry may be E or Z;

A, A', and C are independently H, C₁–C₂₀ acylamino, C₁–C₂₀ acyloxy, C₁–C₂₀ alkoxy carbonyl, C₁–C₂₀ alkoxy, C₁–C₂₀ linear or branched alkylamino, C₁–C₂₀ alkylcarboxylamino, C₁–C₂₀ carbalkoxy; carboxyl, cyano, halo, hydroxy; and t, u, and w are independently integers from 0 to 3;


SAB
SAB

B and B' are independently H, C₁-C₂₀ acylamino, C₁-C₂₀ acyloxy; C₁-C₂₀ alkanoyl, C₁-C₂₀ alkenoyl, C₁-C₂₀ alkenyl, C₁-C₂₀ alkoxycarbonyl, C₁-C₂₀ linear or branched alkoxy, C₁-C₂₀ linear or branched alkylamino, C₁-C₂₀ alkylcarboxylamino, C₁-C₂₀ carbalkoxy; C₆-C₂₀ aroyl, C₆-C₂₀ aralkanoyl, carboxyl, cyano, halo, hydroxy; and x and y are independently integers from 0 to 3;

cont

R', R'', and R''' are independently H or C₁-C₂₀ linear or branched alkyl or alkenyl groups which may contain substituents, COOH, C₁-C₂₀ alkoxycarbonyl, NH₂, CONH₂, C₁-C₂₀ acylamino, OH, C₁-C₂₀ alkoxy, halo or cyano, X=NH, O, S, S=O, or SO₂.

28. (Amended) A compound of formula III.



wherein stereocenters (designated by *) could be R- or S-;

dotted lines indicate that a double bond may be present or absent, and the double bond geometry may be E or Z;

A and C are independently H, C₁-C₂₀ acylamino, C₁-C₂₀ acyloxy, C₁-C₂₀ linear or branched alkanoyl, C₁-C₂₀ alkoxycarbonyl, C₁-C₂₀ linear or branched alkoxy, C₁-C₂₀ linear or branched alkylamino, C₁-C₂₀ alkylcarboxylamino, C₁-C₂₀ carbalkoxy; carboxyl, cyano, halo, hydroxy; thiol, SOR or SOR₂; and f and g are independently integers from 0 to 3;


B is independently H, C₁-C₂₀ acylamino, C₁-C₂₀ acyloxy, C₁-C₂₀ linear or branched alkanoyl, C₁-C₂₀ linear or branched alkenoyl, C₁-C₂₀ linear or branched alkenyl, C₁-C₂₀

alkoxycarbonyl, C₁–C₂₀ linear or branched alkoxy, C₁–C₂₀ linear or branched alkylamino, C₁–C₂₀ alkylcarboxylamino, C₁–C₂₀ carbalkoxy, C₅–C₂₀ aroyl, C₆–C₂₀ aralkanoyl, carboxyl, cyano, halo, hydroxy; and e is an integer from 1 to 3;

R', R'', and R''' are independently H or C₁–C₂₀ linear and branched alkyl or alkenyl groups which may contain substituents, COOH, C₁–C₂₀ aloxycarbonyl, NH₂, CONH₂, C₁–C₂₀ acylamino, OH, C₁–C₂₀ alkoxy, halo, cyano.

Q7
cont

29. (Amended) A pharmaceutical composition containing a blood glucose lowering effective amount of a compound of the formula III in a pharmaceutically acceptable carrier.



wherein stereocenters (designated by *) are R- or S-;

dotted lines indicate that a double bond may be present or absent, and the double bond geometry may be E or Z;


A and C are independently H, C₁–C₂₀ acylamino, C₁–C₂₀ acyloxy, C₁–C₂₀ linear or branched alkanoyl, C₁–C₂₀ aloxycarbonyl, C₁–C₂₀ linear or branched alkoxy, C₁–C₂₀ linear or branched alkylamino, C₁–C₂₀ alkylcarboxylamino, C₁–C₂₀ carbalkoxy; carboxyl, cyano, halo, hydroxy; thiol, SOR or SOR₂; and f and g are independently integers from 0 to 3;

B is independently H, C₁–C₂₀ acylamino, C₁–C₂₀ acyloxy, C₁–C₂₀ linear or branched alkanoyl, C₁–C₂₀ linear or branched alkenoyl, C₁–C₂₀ linear or branched alkenyl, C₁–C₂₀

alkoxycarbonyl, C₁-C₂₀ linear or branched alkoxy, C₁-C₂₀ linear or branched alkylamino, C₁-C₂₀ alkylcarboxylamino, C₁-C₂₀ carbalkoxy; C₅-C₂₀ aroyl, C₆-C₂₀ aralkanoyl, carboxyl, cyano, halo, hydroxy; and e is an integer from 1 to 3;

R', R'', and R''' are independently H or C₁-C₂₀ linear and branched alkyl or alkenyl groups which may contain substituents, COOH, C₁-C₂₀ aloxycarbonyl, NH₂, CONH₂, C₁-C₂₀ acylamino, OH, C₁-C₂₀ alkoxy, halo, cyano.

30. (Amended) A method for lowering blood glucose in a subject comprising administering to said subject an effective blood glucose lowering amount of a composition of the formula III.



wherein stereocenters (designated by *) could be R- or S-.

dotted lines indicate that a double bond may be present or absent, and the double bond geometry may be E or Z;


A and C are independently H, C₁-C₂₀ acylamino, C₁-C₂₀ acyloxy, C₁-C₂₀ linear or branched alkanoyl, C₁-C₂₀ aloxycarbonyl, C₁-C₂₀ linear or branched alkoxy, C₁-C₂₀ linear or branched alkylamino, C₁-C₂₀ alkylcarboxylamino, C₁-C₂₀ carbalkoxy; carboxyl, cyano, halo, hydroxy; thiol, SOR or SOR₂; and f and g are independently integers from 0 to 3;

B is independently H, C₁-C₂₀ acylamino, C₁-C₂₀ acyloxy; C₁-C₂₀ linear or branched alkanoyl, C₁-C₂₀ linear or branched alkenoyl, C₁-C₂₀ linear or branched alkenyl, C₁-C₂₀

alkoxycarbonyl, C₁-C₂₀ linear or branched alkoxy, C₁-C₂₀ linear or branched alkylamino, C₁-C₂₀ alkylcarboxylamino, C₁-C₂₀ carbalkoxy, C₅-C₂₀ aroyl, C₆-C₂₀ aralkanoyl, carboxyl, cyano, halo, hydroxy; and e is an integer from 1 to 3;

cont.
R', R'', and R''' are independently H or C₁-C₂₀ linear and branched alkyl or alkenyl groups which may contain substituents, COOH, C₁-C₂₀ aloxycarbonyl, NH₂, CONH₂, C₁-C₂₀ acylamino, OH, C₁-C₂₀ alkoxy, halo, cyano.

AS 5/2
47. (Amended) A pharmaceutical composition containing a serum triglyceride lowering effective amount of a compound of the formula II in a pharmaceutically acceptable carrier.



wherein stereocenters * are R or S;

dotted lines indicate that a double bond may be present or absent, and the double bond geometry may be E or Z;


A, A', and C are independently H, C₁-C₂₀ acylamino, C₁-C₂₀ acyloxy, C₁-C₂₀ aloxycarbonyl, C₁-C₂₀ alkoxy, C₁-C₂₀ linear or branched alkylamino, C₁-C₂₀ alkylcarboxylamino, C₁-C₂₀ carbalkoxy; carboxyl, cyano, halo, hydroxy; and t, u, and w are independently integers from 0 to 3;

Sub B2
as cont

B and B' are independently H, C₁-C₂₀ acylamino, C₁-C₂₀ acyloxy, C₁-C₂₀ alkanoyl, C₁-C₂₀ alkenoyl, C₁-C₂₀ alkenyl C₁-C₂₀ alkoxycarbonyl, C₁-C₂₀ linear or branched alkoxy, C₁-C₂₀ linear or branched alkylamino, C₁-C₂₀ alkylcarboxylamino, C₁-C₂₀ carbalkoxy, C₆-C₂₀ aroyl, C₆-C₂₀ aralkanoyl, carboxyl, cyano, halo, hydroxy; and x and y are independently integers from 0 to 3;

R', R'', and R''' are independently H or C₁-C₂₀ linear or branched alkyl or alkenyl groups which may contain substituents, COOH, C₁-C₂₀ alkoxycarbonyl, NH₂, CONH₂, C₁-C₂₀ acylamino, OH, C₁-C₂₀ alkoxy, halo or cyano. X = NH, O, S, S=O, or SO₂.

48. (Amended) A method for lowering serum triglyceride in a subject comprising administering to said subject an effective serum triglyceride lowering amount of a composition of the formula II.



wherein stereocenters * R or S;

dotted lines indicate that a double bond may be present or absent, and the double bond geometry may be E or Z;

A, A', and C are independently H, C₁-C₂₀ acylamino, C₁-C₂₀ acyloxy, C₁-C₂₀ alkoxycarbonyl, C₁-C₂₀ alkoxy, C₁-C₂₀ linear or branched alkylamino, C₁-C₂₀


alkylcarboxylamino, C₁-C₂₀ carbalkoxy; carboxyl, cyano, halo, hydroxy; and t, u, and w are independently integers from 0 to 3;

B and B' are independently H, C₁-C₂₀ acylamino, C₁-C₂₀ acyloxy; C₁-C₂₀ alkanoyl, C₁-C₂₀ alkenoyl, C₁-C₂₀ alkenyl, C₁-C₂₀ alkoxy carbonyl, C₁-C₂₀ linear or branched alkoxy, C₁-C₂₀ linear or branched alkylamino, C₁-C₂₀ alkylcarboxylamino, C₁-C₂₀ carbalkoxy, C₆-C₂₀ aroyl, C₆-C₂₀ aralkanoyl, carboxyl, cyano, halo, hydroxy; and x and y are independently integers from 0 to 3;

R', R'', and R''' are independently H or C₁-C₂₀ linear or branched alkyl or alkenyl groups which may contain substituents, COOH, C₁-C₂₀ alkoxy carbonyl, NH₂, CONH₂, C₁-C₂₀ acylamino, OH, C₁-C₂₀ alkoxy, halo or cyano.

X = NH, O, S, S=O, or SO₂

49. (Amended) A pharmaceutical composition containing a serum triglyceride lowering effective amount of a compound of the formula III in a pharmaceutically acceptable carrier.



wherein stereocenters (designated by *) could be R- or S-.


dotted lines indicate that a double bond may be present or absent, and the double bond geometry may be E or Z;

A and C are independently H, C₁-C₂₀ acylamino, C₁-C₂₀ acyloxy, C₁-C₂₀ linear or branched alkanoyl, C₁-C₂₀ alkoxycarbonyl, C₁-C₂₀ linear or branched alkoxy, C₁-C₂₀ linear or branched alkylamino, C₁-C₂₀ alkylcarboxylamino, C₁-C₂₀ carbalkoxy; carboxyl, cyano, halo, hydroxy; thiol, SOR or SOR₂; and f and g are independently integers from 0 to 3;

B is independently H, C₁-C₂₀ acylamino, C₁-C₂₀ acyloxy; C₁-C₂₀ linear or branched alkanoyl, C₁-C₂₀ linear or branched alkenoyl, C₁-C₂₀ linear or branched alkenyl, C₁-C₂₀ alkoxycarbonyl, C₁-C₂₀ linear or branched alkoxy, C₁-C₂₀ linear or branched alkylamino, C₁-C₂₀ alkylcarboxylamino, C₁-C₂₀ carbalkoxy, C₅-C₂₀ aroyl, C₆-C₂₀ aralkanoyl, carboxyl, cyano, halo, hydroxy; and e is an integer from 1 to 3;

R', R'', and R''' are independently H or C₁-C₂₀ linear and branched alkyl or alkenyl groups which may contain substituents, COOH, C₁-C₂₀ alkoxycarbonyl, NH₂, CONH₂, C₁-C₂₀ acylamino, OH, C₁-C₂₀ alkoxy, halo or cyano.

50. (Amended) A method for lowering serum triglyceride in a subject comprising administering to said subject an effective serum triglyceride lowering amount of a composition of the formula III.



wherein stereocenters (designated by *) could be R- or S-.


dotted lines indicate that a double bond may be present or absent, and the double bond geometry may be E or Z;

A and C are independently H, C₁-C₂₀ acylamino, C₁-C₂₀ acyloxy, C₁-C₂₀ linear or branched alkanoyl, C₁-C₂₀ alkoxycarbonyl, C₁-C₂₀ linear or branched alkoxy, C₁-C₂₀ linear or branched alkylamino, C₁-C₂₀ alkylcarboxylamino, C₁-C₂₀ carbalkoxy; carboxyl, cyano, halo, hydroxy; thiol, SOR or SOR₂; and f and g are independently integers from 0 to 3;

B is independently H, C₁-C₂₀ acylamino, C₁-C₂₀ acyloxy; C₁-C₂₀ linear or branched alkanoyl, C₁-C₂₀ linear or branched alkenoyl, C₁-C₂₀ linear or branched alkenyl, C₁-C₂₀ alkoxycarbonyl, C₁-C₂₀ linear or branched alkoxy, C₁-C₂₀ linear or branched alkylamino, C₁-C₂₀ alkylcarboxylamino, C₁-C₂₀ carbalkoxy, C₅-C₂₀ aroyl, C₆-C₂₀ aralkanoyl, carboxyl, cyano, halo, hydroxy; and e is an integer from 1 to 3;

R', R'', and R''' are independently H or C₁-C₂₀ linear and branched alkyl or alkenyl groups which may contain substituents, COOH, C₁-C₂₀ alkoxycarbonyl, NH₂, CONH₂, C₁-C₂₀ acylamino, OH, C₁-C₂₀ alkoxy, halo or cyano.

67. (Amended) A pharmaceutical composition containing a blood pressure lowering effective amount of a compound of the formula II in a pharmaceutically acceptable carrier.



wherein stereocenters * are R or S;

*SUB 7
B3
A9
cont*

dotted lines indicate that a double bond may be present or absent, and the double bond geometry may be E or Z;


A, A', and C are independently H, C₁-C₂₀ acylamino, C₁-C₂₀ acyloxy, C₁-C₂₀ alkoxy carbonyl, C₁-C₂₀ alkoxy, C₁-C₂₀ linear or branched alkylamino, C₁-C₂₀ alkylcarboxylamino, C₁-C₂₀ carbalkoxy; carboxyl, cyano, halo, hydroxy; and t, u, and w are independently integers from 0 to 3;

B and B' are independently H, C₁-C₂₀ acylamino, C₁-C₂₀ acyloxy; C₁-C₂₀ alkanoyl, C₁-C₂₀ alkenoyl, C₁-C₂₀ alkenyl, C₁-C₂₀ alkoxy carbonyl, C₁-C₂₀ linear or branched alkoxy, C₁-C₂₀ linear or branched alkylamino, C₁-C₂₀ alkylcarboxylamino, C₁-C₂₀ carbalkoxy, C₆-C₂₀ aroyl, C₆-C₂₀ aralkanoyl, carboxyl, cyano, halo, hydroxy; and x and y are independently integers from 0 to 3;

R', R'', and R''' are independently H or C₁-C₂₀ linear or branched alkyl or alkenyl groups which may contain substituents, COOH, C₁-C₂₀ alkoxy carbonyl, NH₂, CONH₂, C₁-C₂₀ acylamino, OH, C₁-C₂₀ alkoxy, halo or cyano.

X = NH, O, S, S=O, or SO₂

68. (Amended) A method for lowering blood pressure in a subject comprising administering to said subject an effective blood pressure lowering amount of a composition of the formula II



wherein stereocenters * are R or S;

dotted lines indicates that a double bond may be present or absent, and the double bond geometry may be E or Z;


A, A', and C are independently H, C₁-C₂₀ acylamino, C₁-C₂₀ acyloxy, C₁-C₂₀ alkoxy carbonyl, C₁-C₂₀ alkoxy, C₁-C₂₀ linear or branched alkylamino, C₁-C₂₀ alkylcarboxylamino, C₁-C₂₀ carbalkoxy; carboxyl, cyano, halo, hydroxy; and t, u, and w are independently integers from 0 to 3;

B and B' are independently H, C₁-C₂₀ acylamino, C₁-C₂₀ acyloxy; C₁-C₂₀ alkanoyl, C₁-C₂₀ alkenoyl, C₁-C₂₀ alkenyl C₁-C₂₀ alkoxy carbonyl, C₁-C₂₀ linear or branched alkoxy, C₁-C₂₀ linear or branched alkylamino, C₁-C₂₀ alkylcarboxylamino, C₁-C₂₀ carbalkoxy, C₆-C₂₀ aroyl, C₆-C₂₀ aralkanoyl, carboxyl, cyano, halo, hydroxy; and x and y are independently integers from 0 to 3;

R', R'', and R''' are independently H or C₁-C₂₀ linear or branched alkyl or alkenyl groups which may contain substituents, COOH, C₁-C₂₀ alkoxy carbonyl, NH₂, CONH₂, C₁-C₂₀ acylamino, OH, C₁-C₂₀ alkoxy, halo or cyano.

X = NH, O, S, S=O, or SO₂.

69. (Amended) A pharmaceutical composition containing a blood pressure lowering effective amount of a compound of the formula III in a pharmaceutically acceptable carrier



wherein stereocenters (designated by *) could be R- or S-.

a
cont


dotted lines indicate that a double bond may be present or absent, and the double bond geometry may be E or Z;

A and C are independently H, C₁-C₂₀ acylamino, C₁-C₂₀ acyloxy, C₁-C₂₀ linear or branched alkanoyl, C₁-C₂₀ alkoxycarbonyl, C₁-C₂₀ linear or branched alkoxy, C₁-C₂₀ linear or branched alkylamino, C₁-C₂₀ alkylcarboxylamino, C₁-C₂₀ carbalkoxy; carboxyl, cyano, halo, hydroxy; thiol, SOR or SOR₂; and f and g are independently integers from 0 to 3;

B is independently H, C₁-C₂₀ acylamino, C₁-C₂₀ acyloxy; C₁-C₂₀ linear or branched alkanoyl, C₁-C₂₀ linear or branched alkenoyl, C₁-C₂₀ linear or branched alkenyl, C₁-C₂₀ alkoxycarbonyl, C₁-C₂₀ linear or branched alkoxy, C₁-C₂₀ linear or branched alkylamino, C₁-C₂₀ alkylcarboxylamino, C₁-C₂₀ carbalkoxy, C₅-C₂₀ aroyl, C₆-C₂₀ aralkanoyl, carboxyl, cyano, halo, hydroxy; and e is an integer from 1 to 3;

R', R'', and R''' are independently H or C₁-C₂₀ linear and branched alkyl or alkenyl groups which may contain substituents, COOH, C₁-C₂₀ alkoxycarbonyl, NH₂, CONH₂, C₁-C₂₀ acylamino, OH, C₁-C₂₀ alkoxy, halo or cyano.

70. (Amended) A method for lowering blood pressure in a subject comprising administering to said subject an effective blood pressure lowering amount of a composition of the formula III.



wherein stereocenters (designated by *) could be R- or S-.

a
cont
dotted lines indicate that a double bond may be present or absent, and the double bond geometry may be E or Z;

A and C are independently H, C₁-C₂₀ acylamino, C₁-C₂₀ acyloxy, C₁-C₂₀ linear or branched alkanoyl, C₁-C₂₀ alkoxycarbonyl, C₁-C₂₀ linear or branched alkoxy, C₁-C₂₀ linear or branched alkylamino, C₁-C₂₀ alkylcarboxylamino, C₁-C₂₀ carbalkoxy; carboxyl, cyano, halo, hydroxy; thiol, SOR or SOR₂; and f and g are independently integers from 0 to 3;

B is independently H, C₁-C₂₀ acylamino, C₁-C₂₀ acyloxy; C₁-C₂₀ linear or branched alkanoyl, C₁-C₂₀ linear or branched alkenoyl, C₁-C₂₀ linear or branched alkenyl, C₁-C₂₀ alkoxycarbonyl, C₁-C₂₀ linear or branched alkoxy, C₁-C₂₀ linear or branched alkylamino, C₁-C₂₀ alkylcarboxylamino, C₁-C₂₀ carbalkoxy, C₅-C₂₀ aroyl, C₆-C₂₀ aralkanoyl, carboxyl, cyano, halo, hydroxy; and e is an integer from 1 to 3;

R', R'', and R''' are independently H or C₁-C₂₀ linear or branched alkyl or alkenyl groups which may contain substituents, COOH, C₁-C₂₀ alkoxycarbonyl, NH₂, CONH₂, C₁-C₂₀ acylamino, OH, C₁-C₂₀ alkoxy, halo or cyano.